{"id":"dtg-based-arv-regimen-without-abc","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL191973","moleculeType":"Small molecule","molecularWeight":"437.40"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Dolutegravir binds to the HIV integrase enzyme and inhibits its catalytic activity, blocking the strand transfer step of viral integration. This prevents HIV from establishing persistent infection in CD4+ T cells. The regimen formulation without abacavir (ABC) is designed to avoid potential hypersensitivity reactions while maintaining potent antiretroviral activity.","oneSentence":"DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:43.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment-naive or treatment-experienced patients)"}]},"trialDetails":[{"nctId":"NCT03327740","phase":"","title":"PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-09-30","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DTG based ARV regimen without ABC","genericName":"DTG based ARV regimen without ABC","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA. Used for HIV-1 infection (treatment-naive or treatment-experienced patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}